CAU
CTKB icon

Caxton Associates (UK)’s Cytek Biosciences CTKB Stock Holding History

Caxton Associates (UK)’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.9K Buy
+11,931
New +$50.9K ﹤0.01% 730
2026
Q1 		– Sell
-45,376
Closed -$229K – 827
2025
Q4 		$229K Sell
45,376
-48,032
-51% -$223K ﹤0.01% 684
2025
Q3 		$324K Sell
93,408
-10,057
-10% -$37.8K 0.01% 539
2025
Q2 		$352K Buy
103,465
+1,571
+2% +$5.24K 0.01% 509
2025
Q1 		$409K Buy
+101,894
New +$528K 0.01% 543

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Caxton Associates (UK)'s CTKB Position: Q2 2026 in Review

Caxton Associates (UK) opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 11,931 shares worth $52.9K. The stake represents ﹤0.01% of the portfolio and ranks #730 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in CTKB as recently as Q4 2025.

Caxton Associates (UK) first reported a position in CTKB in Q1 2025 and has held it in 5 quarters since. The position peaked at $409K in Q1 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Caxton Associates (UK) held 11,931 shares of Cytek Biosciences worth $52.9K as of Q2 2026.
  • Cytek Biosciences was a new Caxton Associates (UK) position in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #730 holding.
  • Caxton Associates (UK) first reported a position in Cytek Biosciences in Q1 2025 and has held it in 5 quarters since.
  • Caxton Associates (UK)'s Cytek Biosciences position peaked at $409K in Q1 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.